CAMBRIDGE, England, Feb. 1, 2024 /PRNewswire/ -- Maxion Therapeutics ('Maxion'), the biotechnology company developing antibody-based drugs for previously untreatable ion channel- and GPCR-driven diseases, announced today that Dr Arndt Schottelius has been appointed as the new Chief Executive Officer, effective on 1 March 2024, to take the Company to its next phase of development.

英国剑桥，2024年2月1日/PRNewswire/-Maxion Therapeutics（“Maxion”）是一家为以前无法治疗的离子通道和GPCR驱动的疾病开发抗体药物的生物技术公司，今天宣布Arndt Schottelius博士已被任命为新的首席执行官，自2024年3月1日起生效，将公司带入下一个发展阶段。

The appointment is part of a planned succession process, with co-founder Dr John McCafferty transitioning from Chief Executive Officer to Chief Technology Officer after having co-founded Maxion, raised $16 million in initial funding, and established its cutting-edge KnotBody® technology..

此次任命是计划中的继任过程的一部分，联合创始人约翰·麦卡弗蒂博士（Dr John McCafferty）在共同创立Maxion后，从首席执行官过渡到首席技术官，筹集了1600万美元的初始资金，并建立了其尖端的KnotBody®技术。。

Prior to joining Maxion, Arndt has served as the Chief Scientific Officer of Affimed and held executive leadership roles as Executive Vice President of R&D at Kymab (acquired by Sanofi) and Chief Development Officer at MorphoSys as well as senior leadership roles at Genentech. During his 25-year career in the pharmaceutical industry, he established a successful track record of advancing therapeutics from research into early and late-stage clinical developments and in building valuable portfolios of drug candidates and pharma partnerships.

在加入Maxion之前，Arndt曾担任Affimed的首席科学官，并担任Kymab（由赛诺菲收购）研发执行副总裁、MorphoSys首席开发官以及Genentech的高级领导职务。在他25年的制药行业职业生涯中，他成功地将治疗方法从研究推进到早期和晚期临床开发，并建立了有价值的候选药物组合和制药合作伙伴关系。

Arndt has extensive experience in discovery, project and portfolio management, preclinical and clinical development, FDA negotiations and regulatory filings as well as business development..

Arndt在发现、项目和投资组合管理、临床前和临床开发、FDA谈判和监管备案以及业务发展方面拥有丰富经验。。

Arndt studied medicine in Freiburg, Germany and at the Royal Free Hospital in London. He holds PhD and MD degrees from the University of Freiburg, Germany and a Habilitation in Experimental Medicine degree from Ludwig-Maximilian University Munich. Arndt subsequently practised medicine as a resident physician in gastroenterology at the Charité-Universitätsmedizin in Berlin, Germany, and held a research fellowship from the Crohn's & Colitis Foundation of America at the University of North Carolina at Chapel Hill before working in the pharmaceutical industry..

阿恩特在德国弗莱堡和伦敦皇家自由医院学习医学。他拥有德国弗莱堡大学的博士和医学博士学位，以及慕尼黑路德维希·马克西米利安大学的实验医学训练学位。随后，Arndt在德国柏林的Charité-Universitätsmedizin担任肠胃病住院医师，并在制药行业工作之前，在北卡罗莱纳大学教堂山分校获得了美国克罗恩结肠炎基金会的研究奖学金。。

Eva-Lotta Allan, Chair of the Board of Directors commented: 'It is with great pleasure that I, on behalf of the Board, welcome Arndt to Maxion. As we are expanding our portfolio of KnotBodies and driving our lead programme towards the clinic, his leadership and drug development expertise will be invaluable.

董事会主席伊娃·洛塔·艾伦评论道：“我很高兴代表董事会欢迎阿恩特来到Maxion。随着我们扩大KnotBodies的投资组合，推动我们的领先项目走向诊所，他的领导力和药物开发专业知识将是无价的。

I look forward to working with Arndt to shape the vision and drive the Company forward.'.

我期待着与Arndt合作，塑造愿景，推动公司向前发展。”。

Dr John McCafferty, current CEO added: 'I am proud of what we have achieved so far at Maxion, and am pleased to welcome Arndt to the team to guide the transition of the Company into the next stage of our development. We have a unique KnotBody technology which addresses the key challenges in ion channel and GPCR antibody drug discovery and our lead programme is rapidly advancing towards preclinical development.

现任首席执行官约翰·麦卡弗蒂（JohnMcCafferty）博士补充道：“我为我们在Maxion迄今取得的成就感到骄傲，并很高兴欢迎阿恩特（Arndt）加入团队，指导公司过渡到下一个发展阶段。我们拥有独特的KnotBody技术，可解决离子通道和GPCR抗体药物发现中的关键挑战，我们的领先计划正在迅速向临床前发展。

With Arndt's appointment, I am excited to be dedicating more time to further advance the underlying KnotBody technology and enabling new opportunities. The team is keen to work closely with Arndt and benefit from his extensive experience in antibody drug development to ensure we reach our ambitious goals.'.

随着Arndt的任命，我很高兴能投入更多时间来进一步推进底层KnotBody技术并创造新的机会。该团队渴望与Arndt密切合作，并受益于他在抗体药物开发方面的丰富经验，以确保我们实现我们的宏伟目标。”。

Dr Arndt Schottelius, incoming CEO said: 'Maxion's truly revolutionary technology has the unique opportunity to deliver first-in-class and best-in-class protein therapeutics to treat ion channel and GPCR-driven diseases. I am delighted to join Maxion Therapeutics at such an exciting time in the Company's development. I look forward to working with the leadership team and the Board to maximise the value of the Company's proprietary KnotBody technology.'.

即将上任的首席执行官阿恩特·肖特利乌斯（ArndtSchottelius）博士表示：“Maxion真正革命性的技术有着独特的机会，可以提供一流和一流的蛋白质疗法来治疗离子通道和GPCR驱动的疾病。我很高兴在公司发展的如此激动人心的时刻加入Maxion Therapeutics。我期待着与领导团队和董事会合作，最大限度地发挥公司专有KnotBody技术的价值。”。

About Maxion Therapeutics

关于Maxion Therapeutics

Maxion Therapeutics is developing novel biologic medicines for ion channels and GPCRs, which are critical cell surface proteins involved in a wide range of untreated or poorly-treated diseases, including autoimmune conditions and chronic pain. Maxion is applying its patented KnotBody® technology to generate potent, selective, and long-acting antibody-like drugs.

Maxion Therapeutics正在开发用于离子通道和GPCR的新型生物药物，GPCR是涉及多种未经治疗或治疗不佳的疾病（包括自身免疫性疾病和慢性疼痛）的关键细胞表面蛋白。Maxion正在应用其获得专利的KnotBody®技术来产生有效，选择性和长效的抗体样药物。

KnotBody technology combines the benefits of naturally occurring mini-proteins, which have ion channel modulating activity, with antibodies, using state-of-the-art phage and mammalian display technologies. The resulting fusion protein, which combines the drug-like benefits of both molecules, helps address key challenges in ion channel and GPCR drug discovery..

KnotBody技术利用最先进的噬菌体和哺乳动物展示技术，将具有离子通道调节活性的天然存在的微小蛋白质与抗体相结合。由此产生的融合蛋白结合了两种分子的类似药物的优点，有助于解决离子通道和GPCR药物发现中的关键挑战。。

Based at Unity Campus, near Cambridge, UK, Maxion Therapeutics is driven by an experienced team with an excellent track record. CEO and co-founder Dr John McCafferty (previously co-founder of Cambridge Antibody Technology and IONTAS) and CSO and co-founder Dr Aneesh Karatt Vellatt (also co-founder of IONTAS) co-invented KnotBody technology.

Maxion Therapeutics总部位于英国剑桥附近的Unity Campus，由一支经验丰富、业绩良好的团队领导。首席执行官兼联合创始人约翰·麦卡弗蒂（JohnMcCafferty）博士（之前是剑桥抗体技术公司（Cambridge Antibody Technology）和IONTAS公司（IONTAS）的联合创始人）以及CSO和联合创始人阿内什·卡拉特·维拉特（Aneesh Karatt Vellatt）博士（也是IONTAS公司的联合创始人）共同发明了KnotBody技术。

Dr McCafferty previously co-invented antibody phage display, which was the subject of the 2018 Nobel Prize in Chemistry awarded to his co-inventor Sir Gregory Winter. The Company is currently developing its KnotBody pipeline, including candidates with significant potential to be first-in-class and best-in-class therapeutics..

McCafferty博士之前共同发明了抗体噬菌体展示，这是2018年诺贝尔化学奖授予他的共同发明人格雷戈里·温特爵士的主题。该公司目前正在开发其KnotBody管道，其中包括具有成为一流和一流治疗药物的巨大潜力的候选人。。

For more information, visit www.maxiontherapeutics.com

欲了解更多信息，请访问www.maxiontherapeutics.com

Logo - https://mma.prnewswire.com/media/2216694/4286657/Maxion_Therapeutics_Logo.jpg

徽标-https://mma.prnewswire.com/media/2216694/4286657/Maxion_Therapeutics_Logo.jpg

SOURCE Maxion Therapeutics

源Maxion Therapeutics